Sarah Helms
Family · Dallas, NCNPI 1083964290
Payments from drug & device makers
Across 314 payments — averaging $22.82 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Gilead$1K
- Viiv Healthcare Company$836
- AstraZeneca$650
- Novo Nordisk$480
- Bayer$425
- plus $3K from 31 others
What the payments were for
- Food & beverage$7,151100%
- Entertainment$140%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 41 | $1,032 |
| Gilead | 44 | $1,028 |
| Viiv Healthcare Company | 33 | $836 |
| AstraZeneca | 24 | $650 |
| Novo Nordisk | 26 | $480 |
| Bayer | 27 | $425 |
| Otsuka America Pharmaceutical, Inc. | 7 | $274 |
| Merck | 11 | $241 |
| GSK | 6 | $233 |
| Pfizer | 13 | $232 |
| Lilly USA, LLC | 11 | $195 |
| Exact Sciences | 9 | $189 |
| Amgen | 5 | $172 |
| Astellas Pharma US Inc | 7 | $149 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 6 | $118 |
| Janssen Products, LP | 1 | $113 |
| Idorsia Pharmaceuticals US Inc | 6 | $111 |
| Phathom Pharmaceuticals, Inc. | 7 | $103 |
| Boehringer Ingelheim | 4 | $76 |
| Corcept Therapeutics | 4 | $67 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 3 | $54 |
| Sumitomo Pharma America, Inc. | 2 | $48 |
| Abbott | 2 | $45 |
| Johnson & Johnson | 2 | $42 |
| Vanda Pharmaceuticals Inc. | 1 | $30 |
| Tris Pharma Inc | 1 | $23 |
| Daiichi Sankyo Inc. | 1 | $23 |
| Alvogen Inc | 1 | $23 |
| Lundbeck LLC | 1 | $21 |
| Boston Scientific | 1 | $19 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $19 |
| Edwards Lifesciences | 1 | $19 |
| Shield Therapeutics Inc | 1 | $18 |
| Coopersurgical, Inc. | 1 | $16 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Optos, Inc. | 1 | $14 |
| Tolmar, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,165 in reported general payments places this provider in the 95th percentile of 4,522 family providers in North Carolina.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 67 | $89,483 |
| ForteoTeriparatide | 11 | $45,423 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 36 | $43,353 |
| TrulicityDulaglutide | 26 | $30,408 |
| MounjaroTirzepatide | 22 | $28,874 |
| FarxigaDapagliflozin Propanediol | 22 | $28,495 |
| RybelsusSemaglutide | 13 | $24,166 |
| EliquisApixaban | 14 | $15,878 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 14 | $12,267 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 18 | $10,073 |
| LinzessLinaclotide | 12 | $7,610 |
| SymbicortBudesonide/Formoterol Fumarate | 15 | $4,572 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 22 | $4,222 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 78 | $2,389 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 18 | $2,292 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $480 | $113,64980 claims |
| Lilly USA, LLCForteo, Trulicity, Mounjaro | $195 | $104,70459 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $650 | $45,33451 claims |
| GSKTrelegy Ellipta | $233 | $43,35336 claims |
| PfizerEliquis | $232 | $15,87814 claims |
| Boehringer IngelheimStiolto Respimat | $76 | $10,07318 claims |
| AbbVieLinzess | $1,032 | $7,61012 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,522 family providers in North Carolina.
Other family in Dallas
- Leslie ByrneFayetteville$482K
- Michele CerraRaleigh$332K
- Anne LakeArchdale$306K
- Carrie PettitRaleigh$298K
- Nicole RothmanDurham$268K
- Meredith LeaYanceyville$253K
- Jennifer GibbsRaleigh$216K
- Juanita PerkinsDurham$213K
- Teresa DossWilmington$137K
- Debra ScottCharlotte$129K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.